Haleon (NYSE:HLN) Cut to “Hold” at Wall Street Zen

Wall Street Zen lowered shares of Haleon (NYSE:HLN) from a buy rating to a hold rating in a research note released on Saturday morning,Wall Street Zen reports.

A number of other brokerages also recently issued reports on HLN. Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a research report on Friday, September 25th. Morgan Stanley reissued an “overweight” rating on shares of Haleon in a research report on Thursday, August 6th. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Haleon in a report on Wednesday, September 9th. Zacks Research upgraded shares of Haleon from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 19th. Finally, Rothschild & Co Redburn lowered shares of Haleon from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 16th. Two analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy”.

Haleon Stock Performance

NYSE HLN opened at $8.82 on Friday. The company has a market capitalization of $38.81 billion, a price-to-earnings ratio of 22.63, a PEG ratio of 1.99 and a beta of 0.14. The company has a quick ratio of 0.52, a current ratio of 0.69 and a debt-to-equity ratio of 0.38. Haleon has a twelve month low of $8.65 and a twelve month high of $11.28. The stock has a fifty day simple moving average of $9.63 and a 200 day simple moving average of $9.53.

Haleon Cuts Dividend

The firm also recently declared a dividend, which was paid on Thursday, September 17th. Shareholders of record on Friday, August 14th were issued a dividend of $0.0642 per share. This represents a dividend yield of 132.0%. The ex-dividend date was Friday, August 14th. This is a negative change from Haleon’s previous dividend of $0.1307. Haleon’s dividend payout ratio (DPR) is currently 30.77%.

Institutional Trading of Haleon

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Western Wealth Management LLC bought a new stake in Haleon during the 1st quarter valued at $29,000. Annis Gardner Whiting Capital Advisors LLC lifted its position in Haleon by 402.0% in the 1st quarter. Annis Gardner Whiting Capital Advisors LLC now owns 3,002 shares of the company’s stock valued at $30,000 after acquiring an additional 2,404 shares in the last quarter. Parkside Financial Bank & Trust boosted its stake in Haleon by 20.4% during the 2nd quarter. Parkside Financial Bank & Trust now owns 6,233 shares of the company’s stock valued at $58,000 after purchasing an additional 1,055 shares during the last quarter. Gryphon Financial Partners LLC bought a new stake in Haleon during the 1st quarter worth approximately $101,000. Finally, NWF Advisory Services Inc. purchased a new stake in shares of Haleon in the first quarter worth approximately $102,000. 6.67% of the stock is owned by institutional investors.

About Haleon

Haleon plc (NYSE: HLN) is a global consumer healthcare company headquartered in Weybridge, England. The company develops, manufactures and markets over-the-counter medicines, oral healthcare products, nutritional supplements and other consumer health products sold through pharmacies, retailers and e-commerce channels.

Its portfolio includes well-known brands such as Sensodyne, Polident and parodontax in oral healthcare; Advil, Panadol, Voltaren and Theraflu in pain relief and respiratory care; and Centrum and Emergen-C in vitamins, minerals and supplements.